Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Summary by PR Newswire
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a...

2 Articles

PR NewswirePR Newswire
Center

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a...

·United States
Read Full Article
elcorreogallego.eselcorreogallego.es

Europe Approves Tarlatamab for a Very Aggressive Type of Lung Cancer

The European Commission (EC) has just granted a marketing authorisation for tarlatamab (commercial name 'IMDYLLTRA') to Amgen biotechnology as monotherapy to treat adults with extended-stage microcytic lung cancer who require systemic treatment after disease progression during or after first-line treatment with platinum-based chemotherapy.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Monday, June 1, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

European Commission icon

European Commission

Amgen icon

Amgen

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal